Type 2 diabetes
Conditions
Interventions
The AKK bacteria treatment group:Give the patient AKK bacteria capsules, to be taken orally, one capsule per day, with meals.
Semaglutide combined with AKK bacteria treatment group:The patients were treated with semaglutide injection combined with AKK bacteria capsules.
The treatment group of metformin hydrochloride extended-release tablets:The treatment group of metformin hydrochloride extended-release tablets
Semaglutide treatment group:Patients were treated with metformin hydrochloride sustained-release tablets alone at a dose of 0.5g twice daily, and semaglutide was initiated at a d
Sponsors
The Fifth Hospital of Xiamen
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Meeting the diagnostic criteria of the "2024 ADA Standards of Medical Care in Diabetes": Fasting venous blood glucose >= 7.0 mmol/L, or random venous blood glucose >= 11.1 mmol/L, or venous blood glucose at 1 hour during the oral glucose tolerance test (OGTT) >= 11.6 mmol/L, or venous blood glucose at 2 hours during the OGTT >= 11.1 mmol/L, or glycated hemoglobin >= 6.5%; 2. Aged between 18 and 70 years old; 3. Meeting the diagnostic criteria for obesity in the "Expert Consensus on Weight Management of Diabetic Patients (2024 Edition)": Body mass index (BMI) >= 28 kg/m², or abdominal circumference >= 90 cm for men and >= 85 cm for women; 4. Having not taken any weight loss medications within the past 3 months; 5. The patient signs the informed consent form and voluntarily participates in this study.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of pancreatitis, medullary thyroid cancer, retinopathy, or multiple endocrine neoplasia type 2 (MEN2); 2. Patients with severe allergy to semaglutide or those who cannot tolerate it; 3. Patients with type 1 diabetes mellitus, gestational diabetes mellitus, diabetic ketoacidosis, severe infections, malignant tumors, or severe damage to important organs such as the heart, brain, and kidneys; 4. Patients who have received probiotics, lipid-regulating drugs, or antibiotic drugs within one month before enrollment in the study; 5. Patients with gastrointestinal diseases such as diarrhea or constipation; 6. Patients with a history of gastrointestinal surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| body mass;visceral adiposity index,VAI;lipid accumulation index,LAP; | — |
Countries
China
Contacts
Public ContactRongdan Wu
The Fifth Hospital of Xiamen
Outcome results
None listed